

115TH CONGRESS
1ST SESSION

H. R. 1660

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

IN THE HOUSE OF REPRESENTATIVES

MARCH 21, 2017

Mr. SIRES (for himself, Mr. DIAZ-BALART, Mr. CONNOLLY, Mr. ENGEL, Mr. SHERMAN, Mr. CICILLINE, Mr. KEATING, Ms. ROS-LEHTINEN, Mr. DONOVAN, and Mr. SMITH of New Jersey) introduced the following bill; which was referred to the Committee on Foreign Affairs

A BILL

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Global Health Innova-
5 tion Act of 2017”.

1 **SEC. 2. ANNUAL REPORT.**

2 (a) IN GENERAL.—Not later than 180 days after the
3 date of the enactment of this Act, and annually thereafter
4 for a period of 4 years, the Administrator of the United
5 States Agency for International Development shall submit
6 to Congress a report on the development and use of global
7 health innovations in the programs, projects, and activities
8 of the Agency.

9 (b) MATTERS TO BE INCLUDED.—The report re-
10 quired by subsection (a) shall include the following:

11 (1) A description of—

12 (A) the extent to which global health inno-
13 vations described in subsection (a) include
14 drugs, diagnostics, devices, vaccines, electronic
15 and mobile health technologies, and related be-
16 havior change and service delivery innovations;

17 (B) how innovation has advanced the
18 Agency's commitments to achieving an HIV/
19 AIDS-free generation, ending preventable child
20 and maternal deaths, and protecting commu-
21 nities from infectious diseases, as well as
22 furthered by the Global Health Strategic
23 Framework;

24 (C) how goals are set for health product
25 development in relation to the Agency's health-

1 related goals and how progress and impact are
2 measured towards those goals;

3 (D) how the Agency's investments in inno-
4 vation relate to its stated goals; and

5 (E) progress made towards health product
6 development goals.

7 (2) How the Agency, both independently and
8 with partners, donors, and public-private partner-
9 ships, is—

10 (A) leveraging United States investments
11 to achieve greater impact in health innovation;

12 (B) engaging in activities to develop, ad-
13 vance, and introduce affordable, available, and
14 appropriate global health products; and

15 (C) scaling up appropriate health innova-
16 tions in the development pipeline.

17 (3) A description of collaboration and coordina-
18 tion with other Federal departments and agencies,
19 including the Centers for Disease Control and Pre-
20 vention, in support of global health product develop-
21 ment, including a description of how the Agency is
22 working to ensure critical gaps in product develop-
23 ment for global health are being filled.

24 (4) A description of how the Agency is coordi-
25 nating and aligning global health innovation activi-

1 ties between the Global Development Lab, the Cen-
2 ter for Accelerating Innovation and Impact, and the
3 Bureau for Global Health.

○